- CytomX Therapeutics (NASDAQ:CTMX) initiated with Buy rating and $38 (46% upside) price target at SunTrust.
- Globus Medical (NYSE:GMED) initiated with Overweight rating and $65 (17% upside) price target at Cantor Fitzgerald.
- K2M Group Holdings (NASDAQ:KTWO) initiated with Overweight rating and $28 (18% upside) price target at Cantor.
- Mazor Robotics (NASDAQ:MZOR) initiated with Neutral rating and $57 (4% downside risk) price target at Cantor.
- NuVasive (NASDAQ:NUVA) initiated with Neutral rating and $54 (5% upside) price target at Cantor.
- Orthofix International (NASDAQ:OFIX) initiated with Overweight rating and $62 (13% upside) price target at Cantor.
- SeaSpine Holdings (NASDAQ:SPNE) initiated with Overweight rating and $16 (33% upside) price target at Cantor.
- Madrigal Pharmaceuticals (NASDAQ:MDGL) upgraded to Outperform with a $300 (13% upside) price target at Oppenheimer.
- T2 Biosystems (NASDAQ:TTOO) upgraded to Outperform with a $12 (62% upside) price target at Leerink. Shares up 5% premarket.
- AbbVie (NYSE:ABBV) downgraded to Neutral with a $105 (6% upside) price target at Piper Jaffray. Shares down 1% premarket.
- Now read: Madrigal Soars 144% On NASH Results, Is There Room To Run Higher?
Original article